|
June 1, 2005
Dear Colleagues,
It is my pleasure
to announce that World Biotech Forum-a NJ Non-profit Organization is organizing World Biotech Forum 2005: International Forum
on Biotech Commercialization in Greater China/Asia Pacific, to be held at Bove Auditorium, Rutgers Business School-Newark
on July 30, 2005.
In recent years, the Asia Pacific region, especially greater China, has experienced a tremendous
growth rate in the field of biotechnology. Biotech has been seen to be a key driver in improving both the food supply and
the quality of life for this large populace. Without question, there will be many opportunities to take advantage of this
growth, particularly in the sectors of agriculture and healthcare. Although the prospects for growth are generally very positive,
a number of issues need to be addressed before the Asia Pacific region can fully take advantage of this opportunity and reap
the benefits that biotech has to offer. These include the safety of biotech products, clinical trials, health implications,
IPR, regulation of GM products, infrastructure and facilities (developing biotech clusters), skilled manpower, entrepreneurship
culture, and capital and investment availability.
Sponsored by a number of organizations including Rutgers Business
School Entrepreneurship Center, SAPA and others, the International Forum on Biotech Commercialization in Greater China/Asia
Pacific provides a platform to discuss and exchange ideas on some of these issues, specifically in the areas of bio-entrepreneurship,
venture capital and IPR. Speakers from Asia have been invited.
As an industry expert, you are invited to participate
in this unique event as a Sponsor, an Attendant or as a Speaker.
I look forward to hearing from you. For additional
info, please e-mail cmtang@worldbioforum.org.
Sincerely yours,
C. Mark Tang
C. Mark Tang, Ph.D., MBA,
Conference Chair
Co-founder, World Biotech Forum-a NJ Non-profit Organization, President, World Tech Ventures, LLC
Co-Chair,
Melinda Mingus, MD, MBA
Event Co-Host:
Rutgers University, School of Business-Newark & New Brunswick, Entrepreneurship
Center
Media Partner:
Asia Pacific Biotech News (APBN)
Event Supporters:
Rutgers University Asia Center
Sino-America
Pharmaceutical Association (SAPA),
Tristate CACS
and Others...
|
|
Co-Host:
Rutgers Business School, Entreprneurship Center
|
|
|
International Forum on Biotech Commercialization in Greater
China/Asia Pacific(July 30th, 2005)
Online Registration Site: http://www.worldbioforum.org
Venue: Rutgers Business
School-Newark and New Brunswick, The State University of New Jersey,
Bove Auditorium, Engelhard Hall, 1st Floor
190
University Ave, Newark, New Jersey 07102
Conference Program
Conference
Chair:
Dr. C. Mark Tang, Founding Managing Partner, World Technology Ventures, LLC, & Director, Biotech
Commercialization, Rutgers Business School
Program Chairs:
Drs. Melinda Mingus and Mark
Tang, Co-founders, World Biotech Forum
THEME Biotech Commercialization in China/Asia and US
Sat. 7/30/05
07:30 - 4:30 Registration
08:30 - 08:50 Opening Remarks
A 08:50 – 10:40 Life
Sciences Entrepreneurship, Funding and Capital Market
(Introduction and Moderator: C. Mark Tang )
1. Julie
Muraco, Senior Managing Director, Corporate Client Group, NASDAQ Stock Market, New York City, "NASDAQ's Commitment to the
Biotech Industry"
2. Mario Gobbo, Head, Life Sciences, International Finance Corp, World Bank Group, Washington
DC, “Life Sciences in Developing World”
3. C. Mark Tang, Ph.D. Founding Partner, World Technology Ventures, LLC,
New Jersey,“Biotech Funding, Business Models and Industry Trend-Asia Perspectives”
10:40 - 10:50 Networking
Break
B 10:50 - 12:40
Life Science Intellectual Property, Tech Transfer & Commercialization (Moderator: Mark
Rohrbaugh )
4. Kenneth Sonnenfeld, Ph.D., J.D., Partner, Morgan & Fennegan, LLC, New York City, “IP Issues
in Biotech”
5. Mark Rohrbaugh, Ph.D., J.D., Director, Office of Tech Commercialization, National Institute of Health
(NIH), Maryland, "NIH Technology Transfer: Working Globally to Add Value to Early-Stage Technologies"
6. Jerry
M. Kokoshka, Ph.D. Associate Director of Licensing, Columbia University, New York City, “Advancing Early Stage Technology”
7. Yang
Xu, Senior Patent Attorney, Merck, New Jersey, “The Viagra Patent Wars”
12:40 - 13:30 Box Lunch Speech
8. Clarence
Kwan, National Managing Partner of US Chinese Services Group, Deloitte & Touche LLP, New York City
C 13:30 – 15:20 Biotech-Pharma
Partnering: Licensing, Strategic Alliances and Business Development (Moderator: Dr. Melinda Mingus)
9. Christine
T. Fischette, Ph.D., Head of Primary Care Negotiation, Global Business Development & Licensing, Novartis Pharma, New Jersey,
“Issues in Licensing from-to a Big Pharma”
10. Randall B. Sunberg, J.D., Partner, Morgan Lewis, LLP, Princeton,
NJ, “Current Trends and Provisions in Pharma - Biotech Strategic Alliances”
11. Walter Lau, MBA, Manager, External
Science Technology and Licensing, Bristol-Myers Squibb Company, New Jersey
12. Manisha Shah, Hospital Corporation
of America, New York, “Clinical Trials -Patient Safety From Beginning to End”
15:20 - 15:30 Networking Break
D
15:30 – 17:30 China/Asia Biotech-Opportunity and Outlook (Moderator: C. Mark Tang)
13. Franklin C. Salisbury,
Ph.D., President, National Foundation for Cancer Research, Maryland
14. Tom Jin, Ph.D., President, BioPharmaceutical
Solution (BPS), New Jersey and Shanghai
15. Mark Tang, Ph.D. Founding Managing Partner, World Technology Ventures,
LLC, New Jersey
17:30 – 17:50 Mixer
18:00 - 21:00 Dinner (Pre-reservation and payment required)
Note:
Speakers and program are subject to change without notice. For question regarding this conference, please contact: Dr. C.
Mark Tang, cmtang@worldbioforum.org, or Dr. Melinda Mingus, mmingus@gmail.com.
|
Registration Explanations
The conference fee for a student
or visiting scholar is $50. The fee for a professional is $250. Box Lunch will be provided on site a full registration. pre-reservation
and payment are required for dinner reception.
Due to the seat limitation, spots may not be guaranteed if registration
form is received after max seat capacity.
|
